YKL-5-124

CAT:
804-HY-101257-01
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
YKL-5-124 - image 1

YKL-5-124

  • Description:

    YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status[1].
  • UNSPSC:

    12352005
  • Hazard Statement:

    H302, H315, H319, H335
  • Target:

    CDK
  • Type:

    Reference compound
  • Related Pathways:

    Cell Cycle/DNA Damage
  • Applications:

    Neuroscience-Neuromodulation
  • Field of Research:

    Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/ykl-5-124.html
  • Purity:

    99.53
  • Solubility:

    DMSO : 100 mg/mL (ultrasonic)
  • Smiles:

    CC1(C)N(C(N[C@@H](C2=CC=CC=C2)CN(C)C)=O)CC3=C1NN=C3NC(C4=CC=C(NC(C=C)=O)C=C4)=O
  • Molecular Formula:

    C28H33N7O3
  • Molecular Weight:

    515.61
  • Precautions:

    H302, H315, H319, H335
  • References & Citations:

    [1]Olson CM, et al. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chem Biol. 2019 Jun 20;26 (6) :792-803.e10.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Scientific Category:

    Reference compound1
  • Clinical Information:

    No Development Reported
  • Isoform:

    CDK2; CDK7; CDK9
  • Citation 01:

    BioRxiv. 2023 Apr 23.|bioRxiv. 2024 Dec 10:2024.12.09.627542.|bioRxiv. 2025 March 19.|Cell Death Discov. 2025 Mar 4;11 (1) :86.|Cell Discov. 2022 Oct 6;8 (1) :102.|EMBO J. 2025 Sep 8.|Int J Biol Sci. 2024 Aug 19;20 (11) :4513-4531.|Int J Mol Sci. 2023 Apr 10;24 (8) :7009.|iScience. 2024 May 16.|iScience. 2025 Nov 4;28 (12) :113925.|J Biomed Sci. 2022 Feb 14;29 (1) :13.|J Cancer Res Clin Oncol. 2023 Jul;149 (8) :5255-5263.|mBio. 2025 Dec 10;16 (12) :e0289825.|Res Sq. 2024 Jul 29.|Adv Sci (Weinh) . 2024 Dec 10:e2413103.|Cell. 2025 Oct 30;188 (22) :6301-6316.e29.
  • CAS Number:

    [1957203-01-8]